In the EGFR-TKI group, the OR of ILD incidence at any grade with VEGF/VEGFR inhibitors was 0.54 (95% CI, 0.32–0.90; p = 0.02), which represented a significantly lower incidence than that without VEGF/VEGFR inhibitors. The gene discussed is VEGFA; the disease is interstitial lung disease.